Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 16;13:3579–3589. doi: 10.2147/DDDT.S220030

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Gao et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Pre-treatment with DG improves the liver injury upon challenge with Con A. Levels of serum alanine aminotransferase (ALT) (A) aspartate aminotransferase (AST) (B) and total bilirubin (C) in mice treated with different doses of DG before and after Con A administration for 6 hrs and 24 hrs. (D) H&E staining for livers (200x). The black arrows indicate the inflammatory infiltration and necrosis areas. (E) The injury score evaluation was in accordance with pathological staining. Data in the graph indicate P-values between the DG pretreatment and control groups. *, ** mean P < 0.05 and P < 0.01, respectively. N = 8 for each group. This experiment was performed in triplicate.